SCHEMBL4130896

SCHEMBL4130896

Cc1ccc(N=C2NC(=O)C(C(C)(C)c3cccc(C(F)(F)F)c3)S2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.45
TP53 P04637 1/20 0.45
GAA P10253 2/20 0.38
HPGD P15428 1/20 0.37
FFAR1 O14842 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CDK7 P50613 1/20 0.36
CCNH P51946 1/20 0.36
CCNA1 P78396 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
NFE2L2 Q16236 1/20 0.35
KMT2A Q03164 1/20 0.34
ALDH1A1 P00352 2/20 0.34
HTT P42858 2/20 0.34
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4130892 1.00 MAPT (0.45) MAPTTP53GAAHPGDFFAR1
SCHEMBL4136132 0.78 KMT2A (0.57) MAPTTP53GAAKMT2AALDH1A1
SCHEMBL4136135 0.78 KMT2A (0.57) MAPTTP53GAAKMT2AALDH1A1
SCHEMBL4141021 0.78 GAA (0.48) MAPTTP53GAAFFAR1CDK1
SCHEMBL4141017 0.78 GAA (0.48) MAPTTP53GAAFFAR1CDK1
SCHEMBL4132066 0.78 TP53 (0.45) MAPTTP53GAAHPGDNFE2L2
SCHEMBL4132065 0.78 TP53 (0.45) MAPTTP53GAAHPGDNFE2L2
SCHEMBL4130980 0.77 KMT2A (0.46) MAPTTP53GAAKMT2AALDH1A1
SCHEMBL4137361 0.77 MAPT (0.44) MAPTTP53GAAHPGDNFE2L2
SCHEMBL4130977 0.77 KMT2A (0.46) MAPTTP53GAAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156644-A1 Use of thiazole derivatives and analogues in the treatment of cancer BETAGENON AB (SE) 2009-06-18 US disclosed
US-20090136472-A1 Use of thiazole derivatives and analogues in disorders caused by free fatty acids BETAGENON AB (SE) 2009-05-28 US disclosed
WO-2008065409-A2 COMBINATION FOR USE IN THE TREATMENT OF CANCER, COMPRISING TAMOXIFEN OR AN AROMATASE INHIBITOR BETAGENON AB (SE) 2008-06-05 WO disclosed
EP-1906956-A2 USE OF THIAZOLE DERIVATIVES AND ANALOGUES IN DISORDERS CAUSED BY FREE FATTY ACIDS Betagenon AB (SE) 2008-04-09 EP disclosed
EP-1906955-A2 USE OF THIAZOLE DERIVATIVES AND ANALOGUES IN THE TREATMENT OF CANCER Betagenon AB (SE) 2008-04-09 EP disclosed
WO-2007010281-A2 USE OF THIAZOLE DERIVATIVES AND ANALOGUES IN DISORDERS CAUSED BY FREE FATTY ACIDS BETAGENON AB (SE) 2007-01-25 WO disclosed
WO-2007010273-A2 USE OF THIAZOLE DERIVATIVES AND ANALOGUES IN THE TREATMENT OF CANCER BETAGENON AB (SE) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156644-A1 Use of thiazole derivatives and analogues in the treatment of cancer TBXA2R, TSHR, FOLR1 MAPT 3828/4885TP53 44/4885GAA 2671/4885
US-20090136472-A1 Use of thiazole derivatives and analogues in disorders caused by free fatty acids FFAR2, FFAR1, FFAR4 MAPT 2648/4885TP53 4029/4885GAA 1211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.